Vaxart Inc VXRT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VXRT is a good fit for your portfolio.
News
-
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
-
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
-
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
-
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
-
Thinking about buying stock in Cano Health, Vaxart, Macy's, Albemarle Corp, or BioXcel Therapeutics?
-
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
-
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Trading Information
- Previous Close Price
- $1.29
- Day Range
- $1.28–1.41
- 52-Week Range
- $0.53–1.59
- Bid/Ask
- $1.28 / $1.30
- Market Cap
- $226.02 Mil
- Volume/Avg
- 2.8 Mil / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 25.51
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 109
- Website
- https://www.vaxart.com
Comparables
Valuation
Metric
|
VXRT
|
PCVX
|
AVIR
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.45 | 5.25 | 0.61 |
Price/Sales | 25.51 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
VXRT
PCVX
AVIR
Financial Strength
Metric
|
VXRT
|
PCVX
|
AVIR
|
---|---|---|---|
Quick Ratio | 3.11 | 7.43 | 17.86 |
Current Ratio | 3.32 | 7.54 | 18.24 |
Interest Coverage | −57.64 | — | — |
Quick Ratio
VXRT
PCVX
AVIR
Profitability
Metric
|
VXRT
|
PCVX
|
AVIR
|
---|---|---|---|
Return on Assets (Normalized) | −59.01% | −21.69% | −15.46% |
Return on Equity (Normalized) | −85.90% | −23.31% | −16.16% |
Return on Invested Capital (Normalized) | −69.50% | −28.13% | −19.92% |
Return on Assets
VXRT
PCVX
AVIR
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gjztdqvcjp | Jbty | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xgrbccxwn | Hpclqx | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pgjnzxbc | Yyzgrjd | $105.6 Bil | |
MRNA
| Moderna Inc | Zjgddvlp | Hlgxx | $40.8 Bil | |
ARGX
| argenx SE ADR | Hcxffxjf | Wxvpc | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Lgrcfbhgm | Tpxdg | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rjqmvcf | Vlmrjt | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wwtdcscr | Pxkxbbp | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tqhyqxny | Kplrzss | $13.6 Bil | |
INCY
| Incyte Corp | Tdlmwdfb | Tkbmpv | $12.8 Bil |